FDA Expands Guselkumab Label in PsA - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Clinical Report: FDA Expands Guselkumab Label in PsA

Overview

The FDA has approved guselkumab for the inhibition of structural joint damage in adults with active psoriatic arthritis (PsA). This approval is based on the phase 3b APEX trial.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to irreversible joint damage if not adequately treated. The recent FDA approval of guselkumab expands treatment options for patients at risk of joint damage.

Data Highlights

EndpointOutcome
Primary EndpointReduction in joint symptoms
Major Secondary EndpointInhibition of structural damage progression
Radiographic Progression (Week 24 to 48)57% reduction in patients switching from placebo

Key Findings

  • Guselkumab met the primary endpoint of reducing joint symptoms in the APEX trial.
  • The major secondary endpoint showed significant inhibition of structural damage progression compared to placebo.
  • Patients switching from placebo to guselkumab experienced a 57% reduction in radiographic progression from weeks 24 to 48.
  • No new safety signals were identified, consistent with the established safety profile of guselkumab.
  • Guselkumab is the only IL-23 inhibitor with structural inhibition included in its US prescribing information.

Clinical Implications

The approval of guselkumab for structural joint damage inhibition provides clinicians with a new treatment option for managing active PsA.

Conclusion

The FDA's approval of guselkumab for PsA offers a unique option for patients at risk of joint damage.

Related Resources & Content

  1. Johnson & Johnson, FDA Press Release, 2026 -- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
  2. Drug Safety, 2023 -- Evaluating the Long-Term Safety Profile of Guselkumab in Psoriatic Disease: A Comprehensive Review of Eleven Phase II/III Trials Involving Psoriasis and Psoriatic Arthritis
  3. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update - PMC
  4. the new gastroenterologist — Expert spotlights advances in ulcerative colitis treatment
  5. conexiant — Guselkumab Shows Psoriasis Benefit in Darker Skin Tones
  6. Clinical Rheumatology — Sustained Management of Psoriatic Arthritis with Guselkumab Across Various Domains and Patient Profiles: Insights from a Phase 3 Study Post Hoc Analysis
  7. FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
  8. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update - PMC
  9. Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials - PMC

Original Source(s)

FDA Expands Guselkumab Label in PsA

  • by Kathryn Wighton

  • May 29, 2026

Related Content

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs